FDA Adverse Event Injury Summary report: N

ASR ACETABULAR CUPS 54

MDR report key: 2121296 · Received June 1, 2011

Report

Report Number
1818910-2011-09300
Event Type
Injury
Date Received
June 1, 2011
Date of Event
May 2, 2011
Report Date
February 6, 2017
Manufacturer
DEPUY INTERNATIONAL LTD.
Product Code
KWA
PMA / PMN Number
K040627
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
VA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Description of Event or Problem · 1

PT WAS REVISED TO ADDRESS HIP PAIN AND OSTEOLYSIS.

Description of Event or Problem · 1

UPDATE 02/06/2017 ((B)(4)) PFS AND MEDICAL RECORDS RECEIVED. AFTER REVIEW OF THE MEDICAL RECORDS FOR MDR REPORTABILITY, NOTED ELEVATED METAL ION LABS: COBALT, SERUM 46.0 NG/ML AND CHROMIUM, SERUM 18.4 NG/ML. ASR SLEEVE AND STEM ADDED TO COMPLAINT. NOTED PATIENT HAS AN L2-S1 FUSION USING TITANIUM INSTRUMENTATION WITH COBALT-CHROME RODS. NO RIGHT HIP REVISION OPERATIVE NOTE AVAILABLE FOR REVIEW.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ASR ACETABULAR CUPS 54 87KWA KWA DEPUY INTERNATIONAL LTD. NA 2303688

Patients

Seq Age Sex Outcome Treatment
1 NA Required Intervention